nach oben

Current Psychiatry Reports

Erschienen in:

01.11.2015 | Women's Mental Health (CN Epperson, Section Editor)

Premenstrual Dysphoric Disorder: Epidemiology and Treatment

verfasst von: Liisa Hantsoo, C. Neill Epperson

Erschienen in: Current Psychiatry Reports | Ausgabe 11/2015

Einloggen, um Zugang zu erhalten

Abstract

Recently designated as a disorder in the DSM-5, premenstrual dysphoric disorder (PMDD) presents an array of avenues for further research. PMDD’s profile, characterized by cognitive–affective symptoms during the premenstruum, is unique from that of other affective disorders in its symptoms and cyclicity. Neurosteroids may be a key contributor to PMDD’s clinical presentation and etiology, and represent a potential avenue for drug development. This review will present recent literature on potential contributors to PMDD’s pathophysiology, including neurosteroids and stress, and explore potential treatment targets.

Dennerstein L, Lehert P, Heinemann K. Epidemiology of premenstrual symptoms and disorders. Menopause Int. 2012;18:48–51.PubMed

Epperson C, Steiner M, Hartlage SA, Eriksson E, Schmidt PJ, Jones I, et al. Premenstrual dysphoric disorder: evidence for a new category for DSM-5. Am J Psychiatry. 2012;169:465–75.PubMedCentralPubMedCrossRef

American Psychiatric Assn A. Diagnostic and statistical manual of mental disorders (5th ed.). 5th ed. Arlington: American Psychiatric Publishing; 2013.

Hartlage SA, Freels S, Gotman N, Yonkers K. Criteria for premenstrual dysphoric disorder: secondary analyses of relevant data sets. Arch Gen Psychiatry. 2012;69:300–5.PubMedCentralPubMedCrossRef

Freeman EW, Halberstadt SM, Rickels K, Legler JM, Lin H, Sammel MD. Core symptoms that discriminate premenstrual syndrome. J Womens Health (Larchmt). 2011;20:29–35.CrossRef

Endicott J, Nee J, Harrison W. Daily record of severity of problems (DRSP): reliability and validity. Arch Womens Ment Health. 2006;9:41–9.PubMedCrossRef

Feuerstein M, Shaw WS. Measurement properties of the calendar of premenstrual experience in patients with premenstrual syndrome. J Reprod Med. 2002;47:279–89.PubMed

Allen SS, McBride CM, Pirie PL. The shortened premenstrual assessment form. J Reprod Med. 1991;36:769–72.PubMed

O’Brien PMS, Bäckström T, Brown C, Dennerstein L, Endicott J, Epperson CN, et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. Arch Womens Ment Health. 2011;14:13–21.PubMedCentralPubMedCrossRef

10.

ACOG: ACOG Practice Bulletin. Premenstrual syndrome. Clinical management guidelines for obsetrician-gynecologists. Int J Obstet Gynecol. 2001;73:183–91.CrossRef

11.

WHO WHO. The ICD-1 classification of mental, behavioral and developmental disorders. 10th revision (2nd ed.). Geneva, Switzerland; 2004.

12.

Smith SS, Ruderman Y, Frye C, Homanics G, Yuan M. Steroid withdrawal in the mouse results in anxiogenic effects of 3alpha,5beta-THP: a possible model of premenstrual dysphoric disorder. Psychopharmacology (Berl). 2006;186:323–33.CrossRef

13.

Li Y, Pehrson AL, Budac DP, Sánchez C, Gulinello M. A rodent model of premenstrual dysphoria: progesterone withdrawal induces depression-like behavior that is differentially sensitive to classes of antidepressants. Behav Brain Res. 2012;234:238–47.PubMedCrossRef

14.

Schneider T, Popik P. An animal model of premenstrual dysphoric disorder sensitive to antidepressants. Curr Protoc Neurosci. 2009; Chapter 9:Unit 9.31

15.

Bäckström T, Haage D, Löfgren M, Johansson IM, Strömberg J, Nyberg S, et al. Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons. Neuroscience. 2011;191:46–54.PubMedCrossRef

16.••

Schüle C, Nothdurfter C, Rupprecht R. The role of allopregnanolone in depression and anxiety. Prog Neurobiol. 2014;113:79–87. Review article summarizing the importance of allopregnanolone in emotion regulation, potential for therapeutic use in depression and anxiety via GABAergic mechanisms, enhancement of neurogenesis, myelination, neuroprotection, and regulatory effects on HPA axis.PubMedCrossRef

17.

Nelson M, Pinna G. S-norfluoxetine microinfused into the basolateral amygdala increases allopregnanolone levels and reduces aggression in socially isolated mice. Neuropharmacology. 2011;60:1154–9.PubMedCentralPubMedCrossRef

18.

Shanmugan S, Epperson CN. Estrogen and the prefrontal cortex: towards a new understanding of estrogen’s effects on executive functions in the menopause transition. Hum Brain Mapp. 2014;35:847–65.PubMedCentralPubMedCrossRef

19.

Kugaya A, Epperson CN, Zoghbi S, van Dyck CH, Hou Y, Fujita M, et al. Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. Am J Psychiatry. 2003;160:1522–4.PubMedCrossRef

20.

Fink G, Sumner BE, McQueen JK, Wilson H, Rosie R. Sex steroid control of mood, mental state and memory. Clin Exp Pharmacol Physiol. 1998;25:764–75.PubMedCrossRef

21.

Rehavi M, Goldin M, Roz N, Weizman A. Regulation of rat brain vesicular monoamine transporter by chronic treatment with ovarian hormones. Brain Res Mol Brain Res. 1998;57:31–7.PubMedCrossRef

22.

McQueen JK, Wilson H, Fink G. Estradiol-17 beta increases serotonin transporter (SERT) mRNA levels and the density of SERT-binding sites in female rat brain. Brain Res Mol Brain Res. 1997;45:13–23.PubMedCrossRef

23.

Bertrand PP, Paranavitane UT, Chavez C, Gogos A, Jones M, van den Buuse M. The effect of low estrogen state on serotonin transporter function in mouse hippocampus: a behavioral and electrochemical study. Brain Res. 2005;1064:10–20.PubMedCrossRef

24.

Gundlah C, Lu NZ, Bethea CL. Ovarian steroid regulation of monoamine oxidase-A and -B mRNAs in the macaque dorsal raphe and hypothalamic nuclei. Psychopharmacology (Berlin). 2002;160:271–82.CrossRef

25.

Schendzielorz N, Rysa A, Reenila I, Raasmaja A, Mannisto PT. Complex estrogenic regulation of catechol-O-methyltransferase (COMT) in rats. J Physiol Pharmacol. 2011;62:483–90.PubMed

26.

Aguirre CC, Baudry M. Progesterone reverses 17beta-estradiol-mediated neuroprotection and BDNF induction in cultured hippocampal slices. Eur J Neurosci. 2009;29:447–54.PubMedCentralPubMedCrossRef

27.

Bimonte-Nelson HA, Nelson ME, Granholm A-CE. Progesterone counteracts estrogen-induced increases in neurotrophins in the aged female rat brain. Neuroreport. 2004;15:2659–63.PubMedCrossRef

28.

Rapkin AJ, Edelmuth E, Chang LC, Reading AE, McGuire MT, Su TP. Whole-blood serotonin in premenstrual syndrome. Obstet Gynecol. 1987;70:533–7.PubMed

29.

Rasgon N, McGuire M, Tanavoli S, Fairbanks L, Rapkin A. Neuroendocrine response to an intravenous L-tryptophan challenge in women with premenstrual syndrome. Fertil Steril. 2000;73:144–9.PubMedCrossRef

30.

Menkes DB, Coates DC, Fawcett JP. Acute tryptophan depletion aggravates premenstrual syndrome. J Affect Disord. 1994;32:37–44.PubMedCrossRef

31.

Huo L, Straub RE, Roca C, Schmidt PJ, Shi K, Vakkalanka R, et al. Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene. Biol Psychiatry. 2007;62:925–33.PubMedCentralPubMedCrossRef

32.

Dhingra V, Magnay JL, O’Brien PMS, Chapman G, Fryer AA, Ismail KMK. Serotonin receptor 1A C(-1019)G polymorphism associated with premenstrual dysphoric disorder. Obstet Gynecol. 2007;110:788–92.PubMedCrossRef

33.

Gingnell M, Comasco E, Oreland L, Fredrikson M, Sundström-Poromaa I. Neuroticism-related personality traits are related to symptom severity in patients with premenstrual dysphoric disorder and to the serotonin transporter gene-linked polymorphism 5-HTTPLPR. Arch Womens Ment Health. 2010;13:417–23.PubMedCentralPubMedCrossRef

34.

Magnay JL, El-Shourbagy M, Fryer AA, O’Brien S, Ismail KMK. Analysis of the serotonin transporter promoter rs25531 polymorphism in premenstrual dysphoric disorder. Am J Obstet Gynecol. 2010;203:181. e1–5.PubMedCrossRef

35.

Gray JD, Milner TA, McEwen BS. Dynamic plasticity: the role of glucocorticoids, brain-derived neurotrophic factor and other trophic factors. Neuroscience. 2013;239:214–27.PubMedCentralPubMedCrossRef

36.

Colle R, Gressier F, Verstuyft C, Deflesselle E, Lépine J-P, Ferreri F, et al. Brain-derived neurotrophic factor Val66Met polymorphism and 6-month antidepressant remission in depressed Caucasian patients. J Affect Disord. 2015;175:233–40.PubMedCrossRef

37.

Harrisberger F, Smieskova R, Schmidt A, Lenz C, Walter A, Wittfeld K, et al. BDNF Val66Met polymorphism and hippocampal volume in neuropsychiatric disorders: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2015;55:107–18.PubMedCrossRef

38.

Elfving B, Buttenschøn HN, Foldager L, Poulsen PHP, Andersen JH, Grynderup MB, et al. Depression, the Val66Met polymorphism, age, and gender influence the serum BDNF level. J Psychiatr Res. 2012;46:1118–25.PubMedCrossRef

39.

Carbone DL, Handa RJ. Sex and stress hormone influences on the expression and activity of brain-derived neurotrophic factor. Neuroscience. 2013;239:295–303.PubMedCentralPubMedCrossRef

40.

Pilar-Cuéllar F, Vidal R, Pazos A. Subchronic treatment with fluoxetine and ketanserin increases hippocampal brain-derived neurotrophic factor, β-catenin and antidepressant-like effects. Br J Pharmacol. 2012;165:1046–57.PubMedCentralPubMedCrossRef

41.

Deuschle M, Gilles M, Scharnholz B, Lederbogen F, Lang UE, Hellweg R. Changes of serum concentrations of brain-derived neurotrophic factor (BDNF) during treatment with venlafaxine and mirtazapine: role of medication and response to treatment. Pharmacopsychiatry. 2013;46:54–8.PubMed

42.••

Comasco E, Hahn A, Ganger S, Gingnell M, Bannbers E, Oreland L, et al. Emotional fronto-cingulate cortex activation and brain derived neurotrophic factor polymorphism in premenstrual dysphoric disorder. Hum Brain Mapp. 2014;35:4450–8. PMDD women with the BDNF Val66Met Met allele had lower fronto-cingulate cortex activation during the luteal phase compared to female controls with the Met allele.PubMedCrossRef

43.

Oral E, Kirkan TS, Yildirim A, Kotan Z, Cansever Z, Ozcan H, et al. Serum brain-derived neurotrophic factor differences between the luteal and follicular phases in premenstrual dysphoric disorder. Gen Hosp Psychiatry. 2015;37:266–72.PubMedCrossRef

44.

Cubeddu A, Bucci F, Giannini A, Russo M, Daino D, Russo N, et al. Brain-derived neurotrophic factor plasma variation during the different phases of the menstrual cycle in women with premenstrual syndrome. Psychoneuroendocrinology. 2011;36:523–30.PubMedCrossRef

45.

Pilver CE, Levy BR, Libby DJ, Desai RA. Posttraumatic stress disorder and trauma characteristics are correlates of premenstrual dysphoric disorder. Arch Womens Ment Health. 2011;14:383–93.PubMedCentralPubMedCrossRef

46.••

Bertone-Johnson ER, Whitcomb BW, Missmer SA, Manson JE, Hankinson SE, Rich-Edwards JW. Early life emotional, physical, and sexual abuse and the development of premenstrual syndrome: a longitudinal study. J Womens Health (Larchmt). 2014;23:729–39. History of emotional and physical abuse were strongly correlated with moderate to severe PMS.CrossRef

47.

Segebladh B, Bannbers E, Kask K, Nyberg S, Bixo M, Heimer G, et al. Prevalence of violence exposure in women with premenstrual dysphoric disorder in comparison with other gynecological patients and asymptomatic controls. Acta Obstet Gynecol Scand. 2011;90:746–52.PubMedCrossRef

48.

Klatzkin RR, Morrow AL, Light KC, Pedersen CA, Girdler SS. Associations of histories of depression and PMDD diagnosis with allopregnanolone concentrations following the oral administration of micronized progesterone. Psychoneuroendocrinology. 2006;31:1208–19.PubMedCrossRef

49.

Crowley SK, Girdler SS. Neurosteroid, GABAergic and hypothalamic pituitary adrenal (HPA) axis regulation: what is the current state of knowledge in humans? Psychopharmacology (Berl). 2014;231:3619–34.CrossRef

50.

Girdler SS, Straneva PA, Light KC, Pedersen CA, Morrow AL. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol Psychiatry. 2001;49:788–97.PubMedCrossRef

51.

Serra M, Sanna E, Mostallino MC, Biggio G. Social isolation stress and neuroactive steroids. Eur Neuropsychopharmacol. 2007;17:1–11.PubMedCrossRef

52.

Evans J, Sun Y, McGregor A, Connor B. Allopregnanolone regulates neurogenesis and depressive/anxiety-like behaviour in a social isolation rodent model of chronic stress. Neuropharmacology. 2012;63:1315–26.PubMedCrossRef

53.

Porcu P, O’Buckley TK, Alward SE, Marx CE, Shampine LJ, Girdler SS, et al. Simultaneous quantification of GABAergic 3alpha,5alpha/3alpha,5beta neuroactive steroids in human and rat serum. Steroids. 2009;74:463–73.PubMedCentralPubMedCrossRef

54.•

Wium-Andersen MK, Orsted DD, Nielsen SF, Nordestgaard BG. Elevated C-reactive protein levels, psychological distress, and depression in 73, 131 individuals. JAMA Psychiatry. 2013;70:176–84. Large-scale study that found elevated CRP was associated with increased risk for depression in the general population.PubMedCrossRef

55.

O’Brien SM, Fitzgerald P, Scully P, Landers A, Scott LV, Dinan TG. Impact of gender and menstrual cycle phase on plasma cytokine concentrations. Neuroimmunomodulation. 2007;14:84–90.PubMedCrossRef

56.

Northoff H, Symons S, Zieker D, Schaible EV, Schäfer K, Thoma S, et al. Gender- and menstrual phase dependent regulation of inflammatory gene expression in response to aerobic exercise. Exerc Immunol Rev. 2008;14:86–103.PubMed

57.

Gaskins AJ, Wilchesky M, Mumford SL, Whitcomb BW, Browne RW, Wactawski-Wende J, et al. Endogenous reproductive hormones and C-reactive protein across the menstrual cycle: the BioCycle study. Am J Epidemiol. 2012;175:423–31.PubMedCentralPubMedCrossRef

58.

Wander K, Brindle E, O’Connor KA. C-reactive protein across the menstrual cycle. Am J Phys Anthropol. 2008;136:138–46.PubMedCrossRef

59.

Puder JJ, Blum CA, Mueller B, De Geyter C, Dye L, Keller U. Menstrual cycle symptoms are associated with changes in low-grade inflammation. Eur J Clin Investig. 2006;36:58–64.CrossRef

60.

Jane Z-Y, Chang C-C, Lin H-K, Liu Y-C, Chen W-L. The association between the exacerbation of irritable bowel syndrome and menstrual symptoms in young Taiwanese women. Gastroenterol Nurs. 2011;34:277–86.PubMedCrossRef

61.

Kane SV, Sable K, Hanauer SB. The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study. Am J Gastroenterol. 1998;93:1867–72.PubMedCrossRef

62.

Shourie V, Dwarakanath CD, Prashanth GV, Alampalli RV, Padmanabhan S, Bali S. The effect of menstrual cycle on periodontal health—a clinical and microbiological study. Oral Health Prev Dent. 2012;10:185–92.PubMed

63.

Bertone-Johnson ER, Ronnenberg AG, Houghton SC, Nobles C, Zagarins SE, Takashima-Uebelhoer BB, et al. Association of inflammation markers with menstrual symptom severity and premenstrual syndrome in young women. Hum Reprod. 2014;29:1987–94.PubMedCrossRef

64.•

Berman SM, London ED, Morgan M, Rapkin AJ. Elevated gray matter volume of the emotional cerebellum in women with premenstrual dysphoric disorder. J Affect Disord. 2013;146:266–71. Women with PMDD had greater gray matter volume in the posterior cerebellum compared with controls.PubMedCentralPubMedCrossRef

65.

Jeong H-G, Ham B-J, Yeo HB, Jung I-K, Joe S-H. Gray matter abnormalities in patients with premenstrual dysphoric disorder: an optimized voxel-based morphometry. J Affect Disord. 2012;140:260–7.PubMedCrossRef

66.••

Ossewaarde L, van Wingen GA, Rijpkema M, Bäckström T, Hermans EJ, Fernández G. Menstrual cycle-related changes in amygdala morphology are associated with changes in stress sensitivity. Hum Brain Mapp. 2013;34:1187–93. Among non-PMDD women, gray matter volume in the dorsal left amygdala increased during the luteal phase compared with the follicular phase; this volume increase positively correlated with stress-induced negative affect.PubMedCrossRef

67.

Protopopescu X, Tuescher O, Pan H, Epstein J, Root J, Chang L, et al. Toward a functional neuroanatomy of premenstrual dysphoric disorder. J Affect Disord. 2008;108:87–94.PubMedCrossRef

68.

Gingnell M, Morell A, Bannbers E, Wikström J, Sundström Poromaa I. Menstrual cycle effects on amygdala reactivity to emotional stimulation in premenstrual dysphoric disorder. Horm Behav. 2012;62:400–6.PubMedCrossRef

69.

Epperson CN, Haga K, Mason GF, Sellers E, Gueorguieva R, Zhang W, et al. Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry. 2002;59:851–8.PubMedCrossRef

70.••

Liu B, Wang G, Gao D, Gao F, Zhao B, Qiao M, et al. Alterations of GABA and glutamate-glutamine levels in premenstrual dysphoric disorder: a 3T proton magnetic resonance spectroscopy study. Psychiatry Res. 2015;231:64–70. Significantly lower GABA concentrations in the anterior cingulate cortex, medial prefrontal cortex and left basal ganglia of women with PMDD.PubMedCrossRef

71.••

Gingnell M, Bannbers E, Wikström J, Fredrikson M, Sundström-Poromaa I. Premenstrual dysphoric disorder and prefrontal reactivity during anticipation of emotional stimuli. Eur Neuropsychopharmacol. 2013;23:1474–83. PMDD women showed enhanced dorsolateral prefrontal cortex reactivity during the anticipation of negative stimuli during the luteal phase, which was positively correlated with progesterone levels.PubMedCrossRef

72.••

Baller EB, Wei S-M, Kohn PD, Rubinow DR, Alarcón G, Schmidt PJ, et al. Abnormalities of dorsolateral prefrontal function in women with premenstrual dysphoric disorder: a multimodal neuroimaging study. Am J Psychiatry. 2013;170:305–14. PMDD patients showed greater dorsolateral prefrontal cortex activation than control subjects, which may represent a risk factor for PMDD.PubMedCentralPubMedCrossRef

73.

Epperson C, Pittman B, Czarkowski KA, Stiklus S, Krystal JH, Grillon C. Luteal-phase accentuation of acoustic startle response in women with premenstrual dysphoric disorder. Neuropsychopharmacology. 2007;32:2190–8.PubMedCentralPubMedCrossRef

74.

Kask K, Gulinello M, Bäckström T, Geyer MA, Sundström-Poromaa I. Patients with premenstrual dysphoric disorder have increased startle response across both cycle phases and lower levels of prepulse inhibition during the late luteal phase of the menstrual cycle. Neuropsychopharmacology. 2008;33:2283–90.PubMedCrossRef

75.

Huang Y, Zhou R, Wu M, Wang Q, Zhao Y. Premenstrual syndrome is associated with blunted cortisol reactivity to the TSST. Stress. 2015;1–9.

76.

Lee EE, Nieman LK, Martinez PE, Harsh VL, Rubinow DR, Schmidt PJ. ACTH and cortisol response to Dex/CRH testing in women with and without premenstrual dysphoria during GnRH agonist-induced hypogonadism and ovarian steroid replacement. J Clin Endocrinol Metab. 2012;97:1887–96.PubMedCentralPubMedCrossRef

77.••

Segebladh B, Bannbers E, Moby L, Nyberg S, Bixo M, Bäckström T, et al. Allopregnanolone serum concentrations and diurnal cortisol secretion in women with premenstrual dysphoric disorder. Arch Womens Ment Health. 2013. PMDD women with high serum levels of ALLO had blunted cortisol.

78.

Maeng LY, Milad MR. Sex differences in anxiety disorders: interactions between fear, stress, and gonadal hormones. Horm Behav. 2015.

79.

Brown J, O’Brien PMS, Marjoribanks J, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2009; CD001396.

80.

Shah NR, Jones JB, Aperi J, Shemtov R, Karne A, Borenstein J. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstet Gynecol. 2008;111:1175–82.PubMedCentralPubMedCrossRef

81.••

Marjoribanks J, Brown J, O’Brien PMS, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2013;6:CD001396. Cochrane review finding that SSRIs are effective in reducing premenstrual symptoms with luteal or continuous dosing.PubMed

82.

Kleinstäuber M, Witthöft M, Hiller W. Cognitive-behavioral and pharmacological interventions for premenstrual syndrome or premenstrual dysphoric disorder: a meta-analysis. J Clin Psychol Med Settings. 2012;19:308–19.PubMedCrossRef

83.

Halbreich U. Selective serotonin reuptake inhibitors and initial oral contraceptives for the treatment of PMDD: effective but not enough. CNS Spectr. 2008;13:566–72.PubMedCrossRef

84.

Landén M, Thase ME. A model to explain the therapeutic effects of serotonin reuptake inhibitors: the role of 5-HT2 receptors. Psychopharmacol Bull. 2006;39:147–66.PubMed

85.

Steinberg EM, Cardoso GMP, Martinez PE, Rubinow DR, Schmidt PJ. Rapid response to fluoxetine in women with premenstrual dysphoric disorder. Depress Anxiety. 2012;29:531–40.PubMedCentralPubMedCrossRef

86.

Griffin LD, Mellon SH. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci U S A. 1999;96:13512–7.PubMedCentralPubMedCrossRef

87.

Trauger JW, Jiang A, Stearns BA, LoGrasso PV. Kinetics of allopregnanolone formation catalyzed by human 3 alpha-hydroxysteroid dehydrogenase type III (AKR1C2). Biochemistry. 2002;41:13451–9.PubMedCrossRef

88.

Freeman EW. Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder. CNS Drugs. 2004;18:453–68.PubMedCrossRef

89.

Kornstein SG, Pearlstein TB, Fayyad R, Farfel GM, Gillespie JA. Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: efficacy of 3 dosing strategies. J Clin Psychiatry. 2006;67:1624–32.PubMedCrossRef

90.

Landén M, Nissbrandt H, Allgulander C, Sörvik K, Ysander C, Eriksson E. Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology. 2007;32:153–61.PubMedCrossRef

91.

Ravindran LN, Woods S-A, Steiner M, Ravindran AV. Symptom-onset dosing with citalopram in the treatment of premenstrual dysphoric disorder (PMDD): a case series. Arch Womens Ment Health. 2007;10:125–7.PubMedCrossRef

92.

Yonkers KA, Holthausen GA, Poschman K, Howell HB. Symptom-onset treatment for women with premenstrual dysphoric disorder. J Clin Psychopharmacol. 2006;26:198–202.PubMedCrossRef

93.

Freeman EW, Sondheimer SJ, Sammel MD, Ferdousi T, Lin H. A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. J Clin Psychiatry. 2005;66:769–73.PubMedCrossRef

94.•

Lovick T. SSRIs and the female brain—potential for utilizing steroid-stimulating properties to treat menstrual cycle-linked dysphorias. J Psychopharmacol (Oxford). 2013;27:1180–5. Proposes steroid-stimulating properties of SSRIs offer opportunities for new treatments for menstrual cycle-linked disorders in women.CrossRef

95.

Cunningham J, Yonkers KA, O’Brien S, Eriksson E. Update on research and treatment of premenstrual dysphoric disorder. Harv Rev Psychiatry. 2009;17:120–37.PubMedCentralPubMedCrossRef

96.

Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2012;2:CD006586.PubMed

97.

Freeman EW, Halbreich U, Grubb GS, Rapkin AJ, Skouby SO, Smith L, et al. An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome. Contraception. 2012;85:437–45.PubMedCrossRef

98.

Ford O, Lethaby A, Roberts H, Mol BWJ. Progesterone for premenstrual syndrome. Cochrane Database Syst Rev. 2012;3:CD003415.PubMed

99.

Pincus SM, Alam S, Rubinow DR, Bhuvaneswar CG, Schmidt PJ. Predicting response to leuprolide of women with premenstrual dysphoric disorder by daily mood rating dynamics. J Psychiatr Res. 2011;45:386–94.PubMedCentralPubMedCrossRef

100.

Freeman EW, Sondheimer SJ, Rickels K. Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol Bull. 1997;33:303–9.PubMed

101.

Wyatt KM, Dimmock PW, Ismail KMK, Jones PW, O’Brien PMS. The effectiveness of GnRHa with and without “add-back” therapy in treating premenstrual syndrome: a meta analysis. BJOG. 2004;111:585–93.PubMedCrossRef

102.

Busse JW, Montori VM, Krasnik C, Patelis-Siotis I, Guyatt GH. Psychological intervention for premenstrual syndrome: a meta-analysis of randomized controlled trials. Psychother Psychosom. 2009;78:6–15.PubMedCrossRef

103.

Lustyk MKB, Gerrish WG, Shaver S, Keys SL. Cognitive-behavioral therapy for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Arch Womens Ment Health. 2009;12:85–96.PubMedCrossRef

104.•

Kim DR, Hantsoo L, Thase ME, Sammel M, Epperson CN. Computer-assisted cognitive behavioral therapy for pregnant women with major depressive disorder. J Womens Health (Larchmt). 2014;23:842–8. Internet-based cognitive-behavioral therapy reduces burden on the patient in female-specific affective disorder.CrossRef

105.•

Kues JN, Janda C, Kleinstäuber M, Weise C. Internet-based cognitive behavioural self-help for premenstrual syndrome: study protocol for a randomised controlled trial. Trials. 2014;15:472. Proposed criteria for internet based CBT program for PMS/PMDD.PubMedCentralPubMedCrossRef

106.•

Yonkers KA, Pearlstein TB, Gotman N. A pilot study to compare fluoxetine, calcium, and placebo in the treatment of premenstrual syndrome. J Clin Psychopharmacol. 2013;33:614–20. Placebo-controlled study showing calcium carbonate reduced PMS symptoms, but not to the degree of fluoxetine.PubMedCrossRef

107.•

Sohrabi N, Kashanian M, Ghafoori SS, Malakouti SK. Evaluation of the effect of omega-3 fatty acids in the treatment of premenstrual syndrome: “a pilot trial.”. Complement Ther Med. 2013;21:141–6. A randomized double blind controlled trial showing that after 45 days of taking two grams omega-3 fatty acids daily, women with PMS showed decreased depression, anxiety, and cognitive symptoms.PubMedCrossRef

108.

Dante G, Facchinetti F. Herbal treatments for alleviating premenstrual symptoms: a systematic review. J Psychosom Obstet Gynaecol. 2011;32:42–51.PubMedCrossRef

109.

Daley A. Exercise and premenstrual symptomatology: a comprehensive review. J Womens Health (Larchmt). 2009;18:895–9.CrossRef

110.

Bäckström T, Bixo M, Johansson M, Nyberg S, Ossewaarde L, Ragagnin G, et al. Allopregnanolone and mood disorders. Prog Neurobiol. 2014;113:88–94.PubMedCrossRef

Titel: Premenstrual Dysphoric Disorder: Epidemiology and Treatment
verfasst von: Liisa Hantsoo
C. Neill Epperson
Publikationsdatum: 01.11.2015
Verlag: Springer US
Erschienen in: Current Psychiatry Reports / Ausgabe 11/2015
Print ISSN: 1523-3812
Elektronische ISSN: 1535-1645
DOI: https://doi.org/10.1007/s11920-015-0628-3

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2015

The Preeminence of Early Life Trauma as a Risk Factor for Worsened Long-Term Health Outcomes in Women

Blogging and Social Media for Mental Health Education and Advocacy: a Review for Psychiatrists

Substance Use in the Perinatal Period

GABAA Receptor-Modulating Steroids in Relation to Women’s Behavioral Health